CTOs on the Move

Uroplasty

www.uroplasty.com

 
Uroplasty is a global medical company committed to offering transformative treatment options through specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Uroplasty’s products include the Urgent® PC Neuromodulation System, a non-drug, non-surgical office-based treatment for Overactive Bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Urgent PC is an FDA-cleared system that delivers PTNS (Percutaneous Tibial Nerve Stimulation) and is also indicated for the treatment of fecal incontinence outside the US market. Uroplasty also offers Macroplastique®, an injectable urethral bulking agent ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Oceana Therapeutics

Oceana Therapeutics is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Obstetrix Medical Group

Obstetrix Medical Group is a Campbell, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Care Providers Of Minnesota

Care Providers Of Minnesota is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Berkeley Premium Nutraceuticals

Berkeley Premium Nutraceuticals is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ProKidney

ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III